Outlook Therapeutics announces exec appointments
New Jersey, USA-based Outlook Therapeutics (Nasdaq: OTLK) has announced the appointments of Dr Surendra Sharma as senior vice president, medical affairs, and Glen Olsheim as executive director, commercial excellence.
Outlook Therapeutics is a US biopharmaceutical company working to develop and launch the first approved ophthalmic formulation of bevacizumab for use in retinal indications,
“Outlook Therapeutics is very happy to welcome Surendra and Glen to our growing executive leadership team. Their respective backgrounds in directing the medical affairs of an ophthalmic portfolio and of driving the successful launch and commercialization of ophthalmic products will be tremendously valuable as we move towards the commercial launch of ONS-5010 ophthalmic bevacizumab, pending its approval by the US FDA,” said Russell Trenary, president and chief executive of Outlook Therapeutics.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze